Author

Vicky Pliaka

National Technical University of Athens

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Systems Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Leonidas G. AlexopoulosiD· 2 shared Ana Mafalda SantosiD· 1 shared Angeliki MiniaiD· 1 shared Athanassios D. VelentzasiD· 1 shared Charlie George BarkeriD· 1 shared Dimitrios J. StravopodisiD· 1 shared Dimitris E MessinisiD· 1 shared Evangelia PetsalakiiD· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSystems Biology

Leonidas G. AlexopoulosORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ARID1A-induced transcriptional reprogramming rewires signalling responses to drug treatment in melanoma

Charlie George Barker, Sumana Sharma, Ana Mafalda Santos, Konstantinos-Stylianos Nikolakopoulos, Athanassios D. Velentzas, Franziska Völlmy, Angeliki Minia, Vicky Pliaka, Maarten A. F. Altelaar, Gavin James Wright, Leonidas G. Alexopoulos, Dimitrios J. Stravopodis, Evangelia Petsalaki

This study reveals how ARID1A-mediated transcriptional rewiring drives resistance to MAPK inhibitors in melanoma by altering signalling pathways, immune interactions, and receptor dynamics, highlighting potential targets for combinatorial therapies.

bioRxiv · Dec 5, 2024 · PreprintSystems Biology

Prediction of combination therapies based on topological modeling of the immune signaling network in Multiple Sclerosis

Martí Bernardo-Faura, Melanie Rinas, Jakob Wirbel, Inna Pertsovskaya, Vicky Pliaka, Dimitris E Messinis, Gemma Vila, Theodore Sakellaropoulos, Wolfgang Faigle, Pernilla Stridh, Janina Ruth Behrens, Tomas P Olsson, Roland Martinꝉ, Friedemann Paul, Leonidas G. Alexopoulos, , Julio Sáez-Rodríguez

The paper predicts combination therapies for MS by modeling patient-specific signaling networks using phosphoproteomics data and identifies TAK1 as a co-druggable target.

Genome Medicine · Jul 16, 2021Peer-reviewedSystems Biology